In Reply: COVID-19 coagulopathy

[摘要] We would like to thank Dr. Katyal for his interest in our article.1 The comments highlight the ongoing uncertainties and urgent need for better data from prospective randomized controlled trials, such as those being developed under the National Heart, Lung, and Blood Institute’s “Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)” program, to guide optimal management of COVID-19-associated coagulopathy.

[学科分类] 卫生学